Pharmacological activation of soluble guanylate cyclase protects the heart against ischemic injury. - Wikidata - wikimedia - TriplyDB

Pharmacological activation of soluble guanylate cyclase protects the heart against ischemic injury.

Pharmacological activation of soluble guanylate cyclase protects the heart against ischemic injury.

http://www.wikidata.org/entity/Q43295132

about

Heme-dependent and independent soluble guanylate cyclase activators and vasodilation.Total aortic arch replacement: superior ventriculo-arterial coupling with decellularized allografts compared with conventional prostheses Functional Characterization of the GUCY1A3 Coronary Artery Disease Risk Locus.cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.Cardioprotective role of P38 MAPK during myocardial infarction via parallel activation of α-crystallin B and Nrf2.Acute ethanol exposure increases the susceptibility of the donor hearts to ischemia/reperfusion injury after transplantation in rats Cardioprotective Effects of Essential Oil of Lavandula angustifolia on Isoproterenol-induced Acute Myocardial Infarction in Rat.Soluble guanylate cyclase-α1 is required for the cardioprotective effects of inhaled nitric oxide.Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease.Mediterranean diet and cardioprotection: the role of nitrite, polyunsaturated fatty acids, and polyphenols.The alpha1 isoform of soluble guanylate cyclase regulates cardiac contractility but is not required for ischemic preconditioning The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus Pathophysiology of hypertension in the absence of nitric oxide/cyclic GMP signaling.Phytochemical screening and evaluation of cardioprotective activity of ethanolic extract of Ocimum basilicum L. (basil) against isoproterenol induced myocardial infarction in rats Role of α-crystallin B as a regulatory switch in modulating cardiomyocyte apoptosis by mitochondria or endoplasmic reticulum during cardiac hypertrophy and myocardial infarction.Superiority of zinc complex of acetylsalicylic acid to acetylsalicylic acid in preventing postischemic myocardial dysfunction.Cinaciguat prevents the development of pathologic hypertrophy in a rat model of left ventricular pressure overload.Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications.Allosteric regulation of nucleotidyl cyclases: an emerging pharmacological target.The cGMP/PKG pathway as a common mediator of cardioprotection: translatability and mechanism.Role of sGC-dependent NO signalling and myocardial infarction risk.Myocardial protection from ischemia-reperfusion injury post coronary revascularization.Targeting vascular (endothelial) dysfunction.Cardioprotective Effect of Ulmus wallichiana Planchon in β-Adrenergic Agonist Induced Cardiac Hypertrophy Acute Catecholamine Exposure Causes Reversible Myocyte Injury Without Cardiac Regeneration.Comparison of soluble guanylate cyclase stimulators and activators in models of cardiovascular disease associated with oxidative stress.A mouse model reveals an important role for catecholamine-induced lipotoxicity in the pathogenesis of stress-induced cardiomyopathy.Exercise training inhibits inflammatory cytokines and more than prevents myocardial dysfunction in rats with sustained beta-adrenergic hyperactivity.Modulation of NFKB1/p50 by ROS leads to impaired ATP production during MI compared to cardiac hypertrophy.Pharmacological preconditioning with gemfibrozil preserves cardiac function after heart transplantation.Influence of cinaciguat on gastrointestinal motility in apo-sGC mice.Administration of zinc complex of acetylsalicylic acid after the onset of myocardial injury protects the heart by upregulation of antioxidant enzymes.Graft preservation with heparinized blood/saline solution induces severe graft dysfunction.Cardioprotection by Intermittent Hypoxia Conditioning: Evidence, Mechanisms and Therapeutic Potential.

P2860

Q27692662-357BFF54-2976-402B-BB08-865824EF2263 Q28541464-C4F65EC7-8760-4A45-B30B-75FBAECFC0AC Q30252419-E3F0CE21-5044-4DBA-8CA1-6AE36932CC12 Q34244951-86A128E3-DC24-4471-8EF2-BAA0B3B9B063 Q34400162-994905D6-6D8B-4964-875D-01B19131001E Q34479341-AD810C41-1DCA-4157-927F-9FBF72A7953C Q34777781-5438E879-EE16-4D81-BC38-8A6EB177DB27 Q34784680-E3B89C63-66BE-4C90-966B-B8CAB64D556E Q35010064-1BE6D2BB-766D-4326-91A7-0E5F2C243F58 Q35053534-FD0C4515-0F80-49DC-9CE9-520FD43C0F6C Q36031657-A8281B84-5954-4C1D-A779-6EE01DEA0193 Q36234790-08B6E25E-3182-4714-9362-B7ABF2EE0820 Q36532454-AD61C72D-36E7-42BE-96CE-615F4E865034 Q36565025-7845B4B9-ABFE-4C5D-80E8-614452C7082D Q36809512-861FEFF6-787F-4B77-BCAF-1A333DB1A843 Q37071400-948A580D-58B4-4704-961A-8FDB1BF44F69 Q37419185-13FC84F6-9738-443B-A3B7-0AA969D38AC3 Q38000562-59A8C70D-7C25-4317-9CB7-DCDB16254BA0 Q38040779-E3A09243-5146-4350-84F5-58658DB06A1C Q38258238-D2D9EB26-FEEE-4900-A5BD-A5A76733BE81 Q38367012-B51C6061-7A53-47DD-AF9F-7890216157C4 Q38552442-B1BE1E69-DC4C-4B19-A98E-0B4C6AE4D7B7 Q38836199-A99C3B69-FC4E-4DEF-B8D5-11AFA9C04777 Q39576954-E451F5CA-67DE-4F55-8E12-D84B653E1B91 Q41112375-EDA79E64-46C4-4973-ADE9-DDA7AD5C7653 Q42075795-EBC1DB65-DEAE-46DE-AF6C-C76016A778C2 Q42514867-743607A9-77A8-4E3B-BAA4-CF9C77EE88D5 Q43074266-87DEB766-4B61-41B1-8153-BFA6DD560B2D Q46326335-E5B92124-4833-4882-93B6-42199FC06576 Q47133234-85E07E8F-73D4-4B91-B54E-B11AA42769E8 Q49047822-91C924C2-96F1-4D8F-B394-4737725BB519 Q53469228-A0520D6D-494D-4F41-B9B5-CE874F2165DF Q53612348-E7BE8558-267F-4849-9912-A3BC873FB792 Q53695762-14212B8F-A570-4C50-80F9-A97311AA807E

P2860

Pharmacological activation of soluble guanylate cyclase protects the heart against ischemic injury.

http://www.wikidata.org/entity/Q43295132

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Pharmacological activation of ...... heart against ischemic injury.

@en

Pharmacological activation of ...... heart against ischemic injury.

@nl

type

label

Pharmacological activation of ...... heart against ischemic injury.

@en

Pharmacological activation of ...... heart against ischemic injury.

@nl

prefLabel

Pharmacological activation of ...... heart against ischemic injury.

@en

Pharmacological activation of ...... heart against ischemic injury.

@nl

P1433

Q43295132-974C31A5-B035-448F-9AA8-B332E6FF33C1

P1476

Q43295132-DAA12C54-1932-4560-A3E5-81E6456F7739

P2093

Q43295132-0E86CAE4-4179-4B5D-82C5-F4402D8EF0DE

Q43295132-4F2FD549-0229-417D-8EA3-1D667A4278D3

Q43295132-5F486EE7-FDF1-4770-90E8-E58C016823FB

Q43295132-620961CC-21E5-4934-93EA-790DB449A35B

Q43295132-6D38F3F3-9956-4A0A-A154-C0A8D0DA5935

Q43295132-8C692D3D-E5C5-4142-9A76-0BB97DB43A7C

Q43295132-8E3C3344-2146-46C6-AA8C-0D1375F72BBB

Q43295132-C8142045-A1EC-4707-B90F-F49150A763C2

Q43295132-EA5BC744-2685-402A-9D4D-CCA0A3CA708F

Q43295132-EFB237FA-091B-48D9-BE6C-092307EAAC9A

P304

Q43295132-57A36B41-4F32-4165-84B9-BA4A1EF63E6B

P31

Q43295132-2F6F878C-C012-45F8-99D1-B26F33E5B578

P356

Q43295132-8691B2A4-A6F1-424E-A901-C730A8E18A07

P407

Q43295132-6B5B8063-CB49-40E3-8BC2-ED7AF0B62350

P433

Q43295132-273D8033-D39A-4F5A-8FB4-C4A629B325A9

P478

Q43295132-99396EBC-1317-4E52-AE45-44FE205A9C34

P577

Q43295132-A4D19248-FFC3-41BE-9D3D-F40B6315657B

P698

Q43295132-727B4E0C-6100-4F8C-81BA-8F4EAD507041

P921

Q43295132-18EB9694-9CE9-47CA-A7E1-F92CEBF56B50

P356

CIRCULATIONAHA.109.870774

P1433

P1476

Pharmacological activation of ...... heart against ischemic injury.

@en

P2093

Beatrice Seidel

http://www.w3.org/2001/XMLSchema#string

Eniko Barnucz

http://www.w3.org/2001/XMLSchema#string

Gábor Szabó

http://www.w3.org/2001/XMLSchema#string

Gábor Veres

http://www.w3.org/2001/XMLSchema#string

Kristóf Hirschberg

http://www.w3.org/2001/XMLSchema#string

Matthias Karck

http://www.w3.org/2001/XMLSchema#string

Philipp Neugebauer

http://www.w3.org/2001/XMLSchema#string

Sevil Korkmaz

http://www.w3.org/2001/XMLSchema#string

Sivakkanan Loganathan

http://www.w3.org/2001/XMLSchema#string

Stefan Zöllner

http://www.w3.org/2001/XMLSchema#string

P304

677-686

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCULATIONAHA.109.870774

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

120

http://www.w3.org/2001/XMLSchema#string

P577

2009-08-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19667237

http://www.w3.org/2001/XMLSchema#string

P921